{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:28Z","timestamp":1753892068136,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008402","name":"Chengdu University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Zhilong Huoxue Tongyu Capsule (ZLHXTY) has been used in clinical treatment of vascular diseases caused by hypertension over 20\u00a0years. However, the specific mechanisms by ZLHXTY alleviate hypertensive retinopathy (HR) needs to be further explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>HR mouse model was established by infusing Ang II via subcutaneously implanted osmotic mini-pumps, followed by oral administration of ZLHXTY (0.35, 0.7, 1.4\u00a0g\/kg\/day) 28\u00a0days for treatment. To assess the impacts of ZLHXTY on retinal neurodegeneration and vascular injury, multiple experiments such as OCTA, ERG and HE staining were performed. Subsequently, network pharmacological and 4D-label-free proteomics to clarify the potential targets and mechanisms of ZLHXTY alleviated HR. Finally, Western blot, ELISA, IF, and other techniques were utilized to detect the expression of proteins related to inflammation, oxidative stress, and NLRP3 inflammasome activation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ZLHXTY significantly alleviated retinal dysfunction, increased retinal blood flow, and mitigated pathological changes such as retinal tissues edema in HR mice. Network pharmacology indicated that ZLHXTY might exert anti-inflammatory and anti-oxidative stress effects through targets such as TNF and NF-\u03baB. Proteomic analysis showed that the differential proteins between the ZL group and the Ang II group were mainly enriched in the immune-inflammatory response, and the main mechanism of which might be related to the assembly of NLRP3 inflammasome. Subsequent <jats:italic>in vivo<\/jats:italic> experiments corroborated that ZLHXTY remarkably attenuated inflammation and oxidative stress damage in retinal tissues. Further experiments demonstrated that ZLHXTY inhibited the NLRP3\/Caspase-1\/GSDMD signaling pathway and related protein expression. Finally, TEM results also verified that ZLHXTY alleviated pyroptosis in retinal cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggest that ZLHXTY by regulating the NLRP3\/Caspase-1\/GSDMD axis, inhibiting pyroptosis, thereby relieving retinal dysfunction and vascular injury in HR mice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1573693","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:07:24Z","timestamp":1747822044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated proteomics analysis and network pharmacology to elucidate the mechanism of Zhilong Huoxue Tongyu Capsule alleviate hypertensive retinopathy in Ang II infusion mice model"],"prefix":"10.3389","volume":"16","author":[{"given":"Jiao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junguo","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"174166","DOI":"10.1016\/j.ejphar.2021.174166","article-title":"Role of pyroptosis in diabetic retinopathy and its therapeutic implications","volume":"904","author":"Al","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3390\/ph16030345","article-title":"A cross talk between the endocannabinoid system and different systems involved in the pathogenesis of hypertensive retinopathy","volume":"16","author":"Alswailmi","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","article-title":"Current understanding of the molecular and cellular pathology of diabetic retinopathy","volume":"17","author":"Antonetti","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jtcme.2023.07.001","article-title":"Zhilong Huoxue Tongyu capsule alleviates myocardial fibrosis by improving endothelial cell dysfunction","volume":"14","author":"Bi","year":"2024","journal-title":"J. Tradit. Complement. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1436999","DOI":"10.3389\/fendo.2024.1436999","article-title":"Gender differences in the relationship between the systemic immune-inflammation index and all-cause and cardiovascular mortality among adults with hypertension: evidence from NHANES 1999-2018","volume":"15","author":"Cheng","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"Cd006127","DOI":"10.1002\/14651858.CD006127.pub3","article-title":"Blood pressure control for diabetic retinopathy","volume":"3","author":"Do","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3390\/ijms19051378","article-title":"Polarised VEGFA signalling at vascular blood\u2013neural barriers","volume":"19","author":"Dragoni","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e935135","DOI":"10.12659\/MSM.935135","article-title":"Impact of arterial hypertension on the eye: a review of the pathogenesis, diagnostic methods, and treatment of hypertensive retinopathy","volume":"28","author":"Dziedziak","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/1120672120934750","article-title":"Role of multifocal electroretinogram in assessment of early retinal dysfunction in hypertensive patients","volume":"31","author":"Farouk","year":"2021","journal-title":"Eur. J. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4510628","DOI":"10.1155\/2020\/4510628","article-title":"High glucose induces the loss of retinal pericytes partly via NLRP3-caspase-1-GSDMD-mediated pyroptosis","volume":"2020","author":"Gan","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"116521","DOI":"10.1016\/j.jep.2023.116521","article-title":"Zhilong Huoxue Tongyu Capsule attenuates hemorrhagic transformation through the let-7f\/TLR4 signaling pathway","volume":"312","author":"Geng","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/s41440-024-01622-w","article-title":"The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy","volume":"47","author":"Kario","year":"2024","journal-title":"Hypertens. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11481-024-10101-5","article-title":"New insights on NLRP3 inflammasome: mechanisms of activation, inhibition, and epigenetic regulation","volume":"19","author":"Kodi","year":"2024","journal-title":"J. Neuroimmune Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"14471","DOI":"10.3390\/ijms232214471","article-title":"Characterization of NLRP3 inflammasome activation in the onset of diabetic retinopathy","volume":"23","author":"Kuo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12886-023-02807-6","article-title":"Positive correlation between hypertensive retinopathy and albuminuria in hypertensive adults","volume":"23","author":"Li","year":"2023","journal-title":"BMC Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12967-024-04877-6","article-title":"Fucoidan modulates SIRT1 and NLRP3 to alleviate hypertensive retinopathy: in vivo and in vitro insights","volume":"22","author":"Li","year":"2024","journal-title":"J. Transl. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e39505","DOI":"10.1016\/j.heliyon.2024.e39505","article-title":"High-intensity interval training and moderate-intensity continuous training alleviate vascular dysfunction in spontaneously hypertensive rats through the inhibition of pyroptosis","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B23","doi-asserted-by":"publisher","first-page":"114219","DOI":"10.1016\/j.intimp.2025.114219","article-title":"Parthenolide ameliorates diabetic retinopathy by suppressing microglia-induced M\u00fcller cell gliosis and inflammation via the NF-\u03baB signalling","volume":"151","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"114234","DOI":"10.1016\/j.jep.2021.114234","article-title":"A systematic review on Zhilong Huoxue Tongyu capsule in treating cardiovascular and cerebrovascular diseases: pharmacological actions, molecular mechanisms and clinical outcomes","volume":"277","author":"Liang","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3981350","DOI":"10.1155\/2022\/3981350","article-title":"Zhilong Huoxue Tongyu capsule alleviated the pyroptosis of vascular endothelial cells induced by ox-LDL through miR-30b-5p\/NLRP3","volume":"2022","author":"Liu","year":"2022","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"153566","DOI":"10.1016\/j.phymed.2021.153566","article-title":"Evaluation of Zhilong Huoxue Tongyu capsule in the treatment of acute cerebral infarction: a systematic review and meta-analysis of randomized controlled trials","volume":"86","author":"Liu","year":"2021","journal-title":"Phytomedicine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1197433","DOI":"10.3389\/fphar.2023.1197433","article-title":"Zhilong Huoxue Tongyu capsule attenuates intracerebral hemorrhage induced redox imbalance by modulation of Nrf2 signaling pathway","volume":"14","author":"Mazhar","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.3390\/ijms22169050","article-title":"The pathogenesis and therapeutic approaches of diabetic neuropathy in the retina","volume":"22","author":"Oshitari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"101151","DOI":"10.1016\/j.preteyeres.2022.101151","article-title":"Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis","volume":"94","author":"Padovani-Claudio","year":"2023","journal-title":"Prog. Retin Eye Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.preteyeres.2024.101263","article-title":"Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives","volume":"101","author":"Sun","year":"2024","journal-title":"Prog. Retin Eye Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog. Retin Eye Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41573-023-00822-2","article-title":"Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets","volume":"23","author":"Vande Walle","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/15384101.2022.2119514","article-title":"Upregulated miR-194-5p suppresses retinal microvascular endothelial cell dysfunction and mitigates the symptoms of hypertensive retinopathy in mice by targeting SOX17 and VEGF signaling","volume":"22","author":"Wan","year":"2023","journal-title":"Cell Cycle"},{"key":"B34","doi-asserted-by":"publisher","first-page":"102438","DOI":"10.1016\/j.redox.2022.102438","article-title":"CXCL1-CXCR2 signalling mediates hypertensive retinopathy by inducing macrophage infiltration","volume":"56","author":"Wang","year":"2022","journal-title":"Redox Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ymthe.2019.09.025","article-title":"Ablation of immunoproteasome \u03b25i subunit suppresses hypertensive retinopathy by blocking ATRAP degradation in mice","volume":"28","author":"Wang","year":"2020","journal-title":"Mol. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.3390\/ijms24021447","article-title":"Optic nerve regeneration in diabetic retinopathy: potentials and challenges ahead","volume":"24","author":"Wu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"8626","DOI":"10.3390\/ijms25168626","article-title":"Mitochondria in retinal ganglion cells: unraveling the metabolic nexus and oxidative stress","volume":"25","author":"Yang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"109701","DOI":"10.1016\/j.biopha.2019.109701","article-title":"GPR174 suppression attenuates retinopathy in angiotensin II (Ang II)-treated mice by reducing inflammation via PI3K\/AKT signaling","volume":"122","author":"Yue","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1007\/s12035-023-03466-w","article-title":"CREG protects retinal ganglion cells loss and retinal function impairment against ischemia-reperfusion injury in mice via akt signaling pathway","volume":"60","author":"Zeng","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"802063","DOI":"10.3389\/fmed.2021.802063","article-title":"Targeting pyroptotic cell death pathways in retinal disease","volume":"8","author":"Zhao","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"107505","DOI":"10.1016\/j.phrs.2024.107505","article-title":"Mechanism and therapeutic targets of circulating immune cells in diabetic retinopathy","volume":"210","author":"Zhao","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0302650","DOI":"10.1371\/journal.pone.0302650","article-title":"Zhilong Huoxue Tongyu capsule improves myocardial ischemia\/reperfusion injury via the PI3K\/AKT\/Nrf2 axis","volume":"19","author":"Zhao","year":"2024","journal-title":"PLoS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1151185","DOI":"10.3389\/fimmu.2023.1151185","article-title":"The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in diabetic retinopathy","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573693\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:07:25Z","timestamp":1747822045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1573693\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1573693"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1573693","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"1573693"}}